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XDH gene mutation is the underlying cause of classical enzymes that catalyze the last two steps of purine degra-
xanthinuria: A second report. dation, that is, oxidation of hypoxanthine to xanthine
Background. Classical xanthinuria is a rare autosomal reces- and xanthine to uric acid. The incidence of inheritedsive disorder characterized by excessive excretion of xanthine
xanthinuria is estimated to be between 1:6,000 andin urine. Type I disease results from the isolated deficiency of
1:69,000 [1]. Three rare autosomal recessive forms ofxanthine dehydrogenase (XDH), and type II results from dual
deficiency of XDH and aldehyde oxidase. The XDH gene has hereditary xanthinuria have been described: classical
been cloned and localized to chromosome 2p22-23. The aim xanthinuria types I and II and a distinct clinical type,
of this study was to characterize the molecular basis of classical molybdenum cofactor deficiency. Classical xanthinuriaxanthinuria in an Iranian-Jewish family.
type I results from an isolated deficiency of xanthineMethods. The apparently unrelated parents originated from
dehydrogenase (XDH), and type II xanthinuria resultsa community in which consanguineous marriages are common.
Subtyping xanthinuria was attempted by homozygosity mapping from a dual deficiency of XDH and the related enzyme
using microsatellite markers D2S352, D2S367, and D2S2374 in aldehyde oxidase (AO) [1]. Traditionally, classical xan-
the vicinity of the XDH gene. Mutation detection was accom-
thinuria is typed by the allopurinol loading test [2]. Thisplished by PCR-SSCP screening of all 36 exons and exon-intron
test assesses the activity of XDH and AO by measuringjunctions of the XDH gene, followed by direct sequencing and
confirmation of sequence alteration by restriction analysis. the conversion of allopurinol to oxypurinol. Oxypurinol
Results. The index case was homozygous for all three micro- is detected in blood and urine of type I patients who
satellite markers analyzed. The expected frequency of this ge- lack XDH activity yet possess intact AO activity. In type
notype in a control population was 0.0002. These results sug-
II patients, who lack both enzymatic activities, oxypuri-gested that xanthinuria in the patient is linked to the XDH
nol is undetectable. The formation of urinary xanthinegene. Consequently, a 1658insC mutation in exon 16 of the
XDH gene was identified. The 1658insC mutation was not calculi, the main clinical feature of classical xanthinuria,
detected in 65 control DNA samples. may present at any age, leading in some cases to renal
Conclusion. A molecular approach to the diagnosis of classi- failure. Other occasionally observed manifestations ofcal xanthinuria type I in a female patient with profound hypour-
classical xanthinuria are arthropathy [3], myopathy [4],icemia is described. Linkage of xanthinuria to the XDH locus
and duodenal ulcer. Still, some patients remain asymp-was demonstrated by homozygosity mapping, and a 1658insC
mutation, predicting a truncated inactive XDH protein, was tomatic throughout their lives [1]. A third type of heredi-
identified. These results reinforce the notion that mutations in tary xanthinuria, molybdenum cofactor deficiency, is
the XDH gene are the underlying cause of classical xanthinuria characterized by a lack of activity of sulfite oxidase intype I.
addition to that of XDH and AO. This triple enzyme
deficiency results in a severe neonatal form of xan-
thinuria associated with neurological features [1].Xanthinuria, excessive excretion of xanthine in urine,
The human XDH cDNA and gene have been clonedresults from an acquired or inherited dysfunction of the
and localized to chromosome 2p22-23 [5–8]. The XDH
gene comprises 36 exons and 35 introns, spans at least
60 kb, and encodes a polypeptide of 1333 amino acids.Key words: uric acid, xanthinuria, linkage analysis, hypouricemia, mo-
lybdenum cofactor deficiency. The mature enzyme is a homodimer with a subunit mo-
lecular weight of about 150,000. Each subunit containsReceived for publication September 3, 1999
four redox active centers: two iron-sulfur, one FAD/and in revised form December 11, 1999
Accepted for publication January 7, 2000 NAD, and one molybdopterin. XDH can be post-transla-
tionally converted to an oxidase form, xanthine oxidaseÓ 2000 by the International Society of Nephrology
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Fig. 1. Biochemical diagnosis of classical
xanthinuria in an Iranian-Jewish family. The
pedigree shows an asymptomatic index case
and her nephew, the product of consanguine-
ous marriage, who presented with nephrolithi-
asis (*). Each column of the table below the
pedigree shows data of the respective sibling
depicted in the pedigree. Note the markedly
reduced jejunal XDH activity and the de-
creased uric acid and increased oxypurines
levels in the serum in the patient.
(XO) [1]. Two mutations in the XDH gene responsible studied. This study was approved by the Helsinki Com-
mittee of the Medical Center.for type I classical xanthinuria were recently identified in
Japanese patients [9]. The gene responsible for classical
DNA preparationxanthinuria type II is unknown.
Xanthinuria, although rare, has now been reported in Genomic DNA was extracted from peripheral blood
over 20 countries, suggesting that it is not confined to leukocytes by a protein desalting method [12].
any specific ethnic group. However, more than two thirds
Microsatellite markers analysisof the cases were reported from Mediterranean and Mid-
dle Eastern countries [1]. In this article, a novel mutation The microsatellite CA repeat markers D2S352,
in the XDH gene in an Iranian-Jewish family previously D2S2374, and D2S367 located in the vicinity of the XDH
diagnosed with classical xanthinuria is described [10, 11]. gene in the interval of 54 to 58 cM on chromosome
To our knowledge, this is the second report in the medi- 2 were analyzed [13]. A CEPH (Center d’Etudes du
cal literature of a mutation in the XDH gene underlying Polymorphisme Humaine) reference sample (Coriel Cell
classical xanthinuria type I and the first mutation de- Repository, Camden, NJ, USA; kindly provided by Dr.
scribed among Jewish people. Debra French, Mount Sinai Medical Center, New York,
NY, USA) was analyzed for comparison of allele sizes
[13]. Alleles were numbered arbitrarily starting with the
METHODS
most slowly moving band observed in the studied sam-
Subjects ples.
Polymerase chain reactions (PCRs) were carried outFour siblings from a previously described Iranian-Jew-
ish family from the city of Shiraz were studied (Fig. 1) in a total volume of 25 mL and contained 100 ng genomic
DNA, 0.2 mmol/L of each primer, 200 mmol/L of each[10, 11]. The apparently unrelated parents died of un-
known causes. The proposita, a 60-year-old female, pre- dNTP, 0.1 unit of Taq DNA Polymerase, 2.5 mL of 103
buffer (AB Epson, Surrey, UK), 1.5 mmol/L MgCl2, andsented with hypertension at the age of 32 years. The
finding of marked hypouricemia during routine blood 0.1 mL 33P-dATP 10 mCi/mL (Amersham, Buckingham-
shire, UK). All PCR reactions were run for 30 cycles. Thetesting and further biochemical analysis led to the diag-
nosis of classical xanthinuria [10, 11]. Xanthinuria was annealing temperature for markers D2S352 and D2S367
was 578C, and for marker D2S2374, the annealing tem-not detected in her siblings. Revised medical history of
the family revealed nephrolithiases in proposita’s perature was 508C. For electrophoretic separation of mi-
crosatellite alleles, 4.5 mL of PCR products diluted 1:4nephew. Thirty-three control subjects of Iranian-Jewish
origin and 32 controls of other Jewish origin were also in stop solution [95% formamide, 20 mmol/L ethylenedi-
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aminetetraacetic acid (EDTA), 0.05% bromophenol allele and an undigested fragment of 146 bp in the mu-
tated allele.blue, 0.05% xylene cyanol] were denatured for three
minutes at 908C, run on 6% sequencing-polyacrylamide
gels, dried in vacuum for one hour at 808C, and autora-
RESULTS
diographed.
Biochemical evaluation
Screening for mutations by SSCP analysis Laboratory evaluation of classical xanthinuria in this
family was previously reported [10, 11] and is brieflyPrimers were designed to amplify by PCR all 36 exons
and exon-intron junctions of the XDH gene [8]. summarized in Figure 1. Uric acid levels of proposita
were 0.2 and 0.42 mg/dL in serum and 22.5 and 8.5 mg inExon 16 was amplified with the following primers:
forward, 59 GCAAGGAAGGAATCAGTGAT 39; re- 24-hour urine collection, on two occasions, as compared
with normal levels in her siblings. Levels of oxypurinesverse, 59 CCAACTCATGTGGCCTGCAA 39.
Polymerase chain reactions were carried out as de- (xanthine and hypoxanthine) in proposita were elevated
both in serum (0.298 mg/dL) and in 24-hour urine collec-scribed here with the following modifications: 0.2 mmol/L
of each primer and 0.2 units of Taq DNA polymerase. All tion (390 mg). The XDH activity, in a biopsy sample
obtained from patient’s jejunal mucosa, assessed by con-PCR reactions were run for 30 cycles at 628C annealing
temperature. version of 8-14C-hypoxanthine to uric acid, was 5.7% of
normal.For SSCP analysis, 5 mL of each amplification product
diluted 1:6 in stop solution were denatured for three
Analysis of linked polymorphic markersminutes at 908C, cooled on ice for three minutes, run on
a Mutation Detection Enhancement (MDE) gel (FMC Analysis of the microsatellite markers D2S352,
D2S2374, and D2S367, encompassing a recombinationBioProducts Rockland, ME, USA) to which 6% glycerol
was added at 420 V for six to seven hours at room temper- distance of about 4 cM near the XDH gene, revealed
that the patient was homozygous for a specific haplotypeature. Gels were dried in vacuum and autoradiographed.
defined by alleles 4, 5, and 7 of these markers, respec-
Direct PCR sequencing tively (Fig. 2). In a collection of 21 Iranian-Jewish control
DNA samples, 7, 8, and 11 different alleles were detectedPolymerase chain reaction products of exon 16 were
isolated using the Wizard PCR preps DNA purification for markers D2S352, D2S2374, and D2S367, respectively
(data not shown). The frequency of the disease-associ-system for rapid purification of DNA fragments (Pro-
mega, Madison, WI, USA). Direct sequencing of geno- ated alleles in the control chromosomes was 0.157 for
D2S352 (N 5 42), 0.583 for D2S2374 (N 5 36), and 0.159mic DNA was performed using the ThermoSequenase
radiolabeled terminator cycle sequencing kit (Amer- for D2S367 (N 5 42). Based on these data and under
the assumption of random association between allelessham, Cleveland, OH, USA), with the same primers used
for the PCR. Sequencing reaction products (3.5 mL) were at these loci, the expected frequency of the disease-char-
acteristic-haplotype (4-5-7) in the Iranian-Jewish popula-denatured for five minutes at 708C, run on 6% polyacryl-
amide gels, dried, and autoradiographed. tion was 0.014. This implies, based on Hardy–Weinberg
equilibrium, an estimated frequency of homozygotes for
Mutation detection by PCR and artificially created this haplotype of 0.0142 5 ,0.0002 among the Iranian
Drd I restriction site Jews.
The forward primer and the PCR reaction conditions
Identification of the XDH gene mutationwere as specified for PCR-SSCP analysis of exon 16. The
reverse primer sequence (59-TTGGAAGAGCTGGA An aberrant SSCP pattern in exon 16 of the XDH gene
was observed in the patient as compared with controlCATCGA-39) was designed with a C to T mismatch
in the sense strand to create a Drd I recognition site samples (Fig. 3A). Direct sequencing of amplified geno-
mic DNA revealed a repeat of seven cytosine nucleotides(GACN4#N2GTC) in the wild-type allele. PCR reactions
were carried out at 558C annealing temperature, resulting in the patient opposed to six in the control DNA, starting
at position 1658 in the XDH cDNA (Fig. 3B) [7]. Thein a product of 146 bp. Following amplification, PCR
products were digested with Drd I (New England Bio- presence of this sequence alteration was confirmed by
an artificially created Drd I RFLP assay (Fig. 3C). Inlabs, Beverly, MA, USA). Digestion occurred in 10 mL
reaction volume, 8 mL of PCR product, 10 units of restric- control DNA, the wild-type allele was characterized by
PCR digestion products of 123 and 23 bp. In contrast,tion endonuclease, and 1 mL 103 buffer (supplied with
the enzyme). The reaction mix was incubated for a mini- in patient’s DNA, the presence of an undigested PCR
product of 146 bp was consistent with homozygosity formum of two hours. Digestion products were separated
on 4% agarose gels. The expected digestion products the mutation. The mutation was absent in 33 Iranian and
32 non-Iranian Jewish control samples (data not shown).are two fragments of 123 and 23 bp in the wild-type
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I xanthinuria. Given the finding of homozygosity for
all polymorphic markers analyzed, we proceeded with
screening for mutations in the XDH gene and, indeed,
identified the disease-causing mutation. We advocate
that, in cases in which homozygosity is expected, linkage
analysis using several markers flanking the XDH gene
can be used as an alternative or as a complementary
approach to the allopurinol loading test in distinguishing
type I from type II xanthinuria. The selection of markers
might be further optimized once a refined map of the
region flanking the XDH gene is available.
The 1658insC insertion in exon 16 of the XDH gene
causes a translation frameshift predicting a truncated
protein of 569 amino acids with an altered C-terminal
amino acid sequence as compared with 1333 amino acids
of the native protein (Fig. 4). The predicted truncated
protein is anticipated to be functionally compromised,
since amino acid residues (encoded by exon 22) needed
for the formation of the putative NAD binding domain,
the molybdopterin binding site (encoded by exons 22
and 23) and the amino acid residues involved in the
conversion of XDH to XO (exons 16, 27, and 36) are
lost [8]. Thus, homozygosity for the 1658insC mutation
in the patient explains the profound hypouricemia and
the excessive xanthine and hypoxanthine accumulation
in her blood and urine. Nevertheless, throughout 28
years of follow-up, the patient has not complained of
any symptom characteristic of xanthinuria. Interestingly,
patient’s nephew presented with nephrolithiasis. In view
of the potential carrier state of nephew’s mother (pa-
tient’s sister) and consanguinity of parents (Fig. 1), he
might be XDH deficient. Unfortunately, family membersFig. 2. Analysis of XDH-linked microsatellite markers. Autoradio-
other than the patient were unavailable for testing.grams show an analysis of microsatellite markers. Allele numbers are
indicated on the right side of each panel. Lane R, reference CEPH The relevance of the molecular genetics of the
DNA. Lane C, control DNA. Lane P, patient DNA. Note that the XDH/XO system is not restricted to xanthinuria. Whilepatient is homozygous for alleles 4, 5, and 7 of markers D2S352 (top),
uric acid generated by XDH is a major component of theD2S2374 (middle), and D2S364 (bottom), respectively, located in the
vicinity of the XDH gene. antioxidant defense mechanisms [14], reactive oxygen
species generated by XO, the oxidase form of the enzyme
[15–17], have been implicated as mediators of cellular
injury in a wide range of clinical conditions such as ische-DISCUSSION
mia reperfusion [18], hypertension [19], and inflamma-
Following the initial finding of a homozygous XDH- tion [20, 21]. XDH/XO is also involved in the metabolism
linked haplotype, we identified a novel 1658insC muta- of N-heterocyclic compounds of pharmacological and
tion in the XDH gene in a female patient affected by toxicological importance. For example, bone marrow
classical xanthinuria. toxicity by azathioprine may be aggravated by XDH
The allopurinol loading test, traditionally employed deficiency [22]. A recent survey of XDH activity sug-
to discern type I from type II xanthinuria, was not feasi- gested XDH deficiency in up to 2% of healthy controls
ble in the patient. Rareness of the disorder, its autosomal [23]. The possibility that genetic variants, polymor-
recessive mode of inheritance and the origin of propos- phisms, or mutations of the XDH/XO system may modu-
ita’s parents from a small, relatively closed Iranian-Jew- late important pathophysiological conditions warrants
ish community of the city of Shiraz, suggested a common further investigation.
ancestor and therefore homozygosity for the defect un-
derlying her disease. Hence, we elected testing for homo- ACKNOWLEDGMENTS
zygosity of markers linked to the XDH locus, as a molec- This information was presented in part at the 62nd National Scien-
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Fig. 3. Identification of 1658insC mutation.
(A) SSCP analysis of exon 16 of the XDH
gene. Note the slower moving band in patient
(lane P) as compared with control DNA (lane
C). (B) Partial nucleotide sequence and pre-
dicted amino acid sequence of exon 16 of the
XDH gene, in the control and patient. An
insertion of a C nucleotide in position 1658 of
the XDH cDNA encoding an altered amino
acid sequence is evident in patient’s DNA.
(C) PCR-Drd I restriction enzyme assay. The
ethidium bromide-stained agarose gel shows
in the patient (lane P) an undigested fragment
of 146 bp as expected for a homozygous
1658insC mutation, while in a control DNA
(lane C) the expected normal digestion prod-
uct of 123 bp.
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